Late Lilly Stock? Here's What $1,000 Could Become in 10 Years
If you’re wondering whether Eli Lilly stock still has room to run, you’re not alone. This guide outlines scenarios fo...
Discover Eli Lilly stock insights from 4 articles covering long-term bets, timing questions, bullishness priced in, and FDA news. Learn what matters and refine portfolio today.
53 articlesIf you’re wondering whether Eli Lilly stock still has room to run, you’re not alone. This guide outlines scenarios fo...
Johnson & Johnson and Eli Lilly reported contrasting Q1 2026 results, pitting a durable, dividend-focused giant again...
Johnson Johnson walking away from a GLP-1 obesity obsession signals a shift to a diversified, potentially more resili...
Eli Lilly faces a pivotal year as its GLP-1 franchise powers revenue growth and new oral therapies expand addressable...
Investors face a choice between a pharmaceutical powerhouse with proven earnings and a high-growth space company unde...
Is Lilly stock undervalued healthcare? This article breaks down the valuation case, growth catalysts, risks, and a pr...
The ADA conference spotlighted Lilly and Novo Nordisk in the GLP-1 race. This deep dive explains what the claims mean...
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
This deep dive looks at why Lilly stock may be a standout pick for growth-focused investors. From a dominant obesity ...
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Eli Lilly stands at a pivotal moment for investors. With a massive market-cap and a growing GLP-1 portfolio, the ques...
Seeking a stock with growth, resilience, and optionality? This article lays out three strong reasons to consider Lill...